[12] Patent
[11] Patent No.:GC0010746  
[45] Date of Publishing the Grant of the Patent: 31/Oct /2019                63/2019  
Number of the Decision to Grant the Patent:2019/156864
Date of the Decision to Grant the Patent:10/Sep/2019

[21] Application No.:GC 2014-27863

[22] Filing Date:3/9/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
6/9/2013
13183385.7

[72] Inventors:1- GRETHER, Uwe،2- KIMBARA, Atsushi،3- NETTEKOVEN, Matthias،4- ROEVER, Stephan،5- ROGERS-EVANS, Mark،6- SCHMITT, Sébastien

[73] Owner: F. Hoffmann - La Roche AG, 124 Grenzacherstrasse , Basle, CH-4070, Switzerland

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.: A61K 31/519, 31/5377; C07D 487/04 (2006.01)

[56] Cited Documents:

-WO 2013/076182 Al (HOFFMANN LA ROCHE [CH]; BISSANTZ CATERINA [FR]; GRETHER UWE [DE]; KIMB) 30 May 2013
-WO 2013/068306 Al (HOFFMANN LA ROCHE [CH]; ADAM JEAN-MICHEL [FR]; BISSANTZ CATERINA [FR];) 16 May 2013
-RODERICK G. WALKER ET AL: High Throughput Screens Yield Small Molecule Inhibitors of Leishmania CRK3:CYC6 Cyclin-Dependent Kinase, PLOS NEGLECTED TROPICAL DISEASES, vol. 5, no. 4, 5 April 2011 (2011-04-05), page e1033,
-Roderick G. Walker ET AL: High Throughput Screens Yield Small Molecule Inhibitors of Leishmania CRK3:CYC6 Cyclin-Dependent Kinase SUPPORTING INFORMATION S1 , PLOS neglected tropical diseases, 5 April 2011
 
Examiner: PH. Sarah A. AlGrainies

[54] Novel triazolo[4,5-d]pyrimidine derivatives
[57] Abstract: The invention relates to a compound of formula (I) (I)wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
No. of claims: 16


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.